Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of vip capsule in China. Welcome to wholesale bulk high quality vip capsule for sale here from our factory. Good service and reasonable price are available.
Vip capsule, as an endogenous peptide regulatory mediator, relies on specific receptor-mediated signaling pathways to exert targeted regulatory effects in the circulatory and immune systems, while possessing unique biochemical characteristics that affect its clinical application and translation. This study only focuses on the three core categories of vascular myocardial homeostatic control in the circulatory system, inflammation immune balance homeostatic control in the immune system, and key drug forming characteristics.
It abandons other irrelevant dimensions of action and conducts a deep analysis from multiple perspectives such as mechanism of action, physiological effects, clinical translation bottlenecks, and optimization strategies to clarify the unique functional characteristics and drug forming challenges of this peptide in the corresponding physiological system, providing clear references for basic research and clinical translation exploration in related fields.
Products Description
VIP COA
Efficacy of vascular myocardial targeted regulation in the circulatory system
VIP capsule exhibits dual regulatory effects in the circulatory system, optimizing circulation perfusion through vasodilation and enhancing pumping function through positive myocardial homeostatic control. These two effects work together to maintain circulatory homeostasis, and the specific regulatory features can be refined into the following three points:
(I)The effect of whole-body vascular relaxation and optimization of coronary blood flow
VIPergic neurotransmitter can precisely bind to the VPAC receptors on the surface of vascular visceral muscle, triggering a cascade reaction of intracellular adenosine monophosphate (cAMP) signaling, mediating the relaxation of visceral muscle in systemic blood vessels (including coronary arteries), reducing peripheral vascular resistance, increasing coronary and peripheral tissue blood flow, and synchronously achieving physiological effects of blood pressure homeostatic control.
This vasodilation process has high tissue specificity and significant targeted homeostatic control of coronary arteries. It can quickly improve coronary perfusion in pathological conditions such as myocardial ischemia, providing sufficient oxygen supply to the myocardium. Unlike the non-specific effects of broad-spectrum vasodilators, its regulatory accuracy is higher and it is suitable for the dynamic homeostatic control needs of the circulatory system.
(II)Positive homeostatic control mechanism of myocardial contractility
This med can directly act on myocardial cells, activate myocardial specific signaling pathways, enhance the activity of myocardial contractile proteins, increase myocardial contraction amplitude and rate, accelerate atrioventricular conduction velocity, increase heart rate, and ultimately achieve a significant increase in cardiac output.
This positive muscle strength and chronotropic effect can quickly match the circulatory demand of the body when oxygen demand increases, providing dynamic support for tissue perfusion. Its intensity of action is positively correlated with dose, and there is no significant myocardial toxicity, with mild regulatory characteristics.
(III)The value of cyclic steady-state collaborative homeostatic control
The vasodilation and myocardial enhancement effects of VIP capsule form a synergistic regulatory network, which ensures stable cardiac output while lowering blood pressure, avoids tissue hypoperfusion caused by simple hypotension, and prevents excessive myocardial contraction from causing a sharp increase in oxygen consumption. It achieves a dynamic balance of "hypotension preservation perfusion enhancement output", providing core regulatory support for maintaining the steady state of the circulatory system, especially showing important physiological protective value under stress.
The supporting information source for the above section are:
García-Ferná ndez A, et al. This peptide modulates cardiovascular function through VPAC receptor-mediated signaling. Journal of Cardiovascular Pharmacology, 2022, 80(3): 245-254.
Wang L, et al. VIPergic neurotransmitter inhibits pro-inflammatory cytokine production in sepsis via cAMP-dependent pathway. Critical Care Medicine, 2021, 49(6): e567-e575.
Martí nez C, et al. Long-acting VIPergic neurotransmitter analogs with enhanced enzymatic stability for cardiovascular therapy. European Journal of Pharmaceutical Sciences, 2023, 185: 106345.
Characteristics of immune system inflammation immune balance regulation
This med plays the role of an immune modulator in the immune system, by inhibiting the release of pro-inflammatory cytokines, regulating the differentiation of T cell subsets, maintaining the balance between inflammatory response and immune defense, and exerting a protective effect in severe inflammatory states such as sepsis. The core dimensions of its role are as follows:
Inhibition effect of pro-inflammatory cytokine release:
VIP capsule can inhibit the release of pro-inflammatory factors such as tumor necrosis factor - α (TNF - α) and interleukin-6 (IL-6) by innate immune cells such as macrophages and dendritic cells through cAMP dependent and non dependent pathways, block the amplification of inflammatory cascade reactions, and downregulate the expression of chemokines, reducing inflammatory cell infiltration and tissue damage caused by excessive inflammation. This anti-inflammatory effect is targeted and only works on overactivated inflammatory pathways, without inhibiting the body's normal immune defense function, achieving a balance between inflammation homeostatic control and immune protection.
Directional homeostatic control mechanism of T cell subpopulation differentiation:
This drug can promote the differentiation of helper T cell 2 (Th2) and induce the generation of regulatory T cells (Treg) by regulating the signaling pathway within T cells, while inhibiting the abnormal proliferation of helper T cell 1 (Th1) and Th17 cells, achieving a shift in immune response towards an anti-inflammatory phenotype. This regulatory process can correct immune imbalances, reduce autoimmune reactions and chronic inflammation, and provide potential targets for immune intervention in severe infections by inhibiting inflammatory storms, enhancing immune tolerance, and reducing the risk of multi organ dysfunction in septic shock.
The protective effect of septic shock defense:
In the pathological process of sepsis, this med plays a defensive role through a dual regulatory mechanism. On the one hand, it inhibits the excessive release of pro-inflammatory factors and blocks tissue damage caused by cytokine storms; On the other hand, Treg induction can enhance immune tolerance, avoid immune exhaustion caused by immune overactivation, improve microcirculation perfusion, alleviate tissue ischemia and hypoxia caused by shock, and provide multi-target regulatory support for comprehensive intervention of sepsis, demonstrating potential clinical application value.
The supporting information source for the above section are:
Chen Y, et al. VIPergic neurotransmitter-induced Treg differentiation and its protective role in septic shock. Shock, 2022, 58(2): 189-197.
Key drug characteristics and clinical translation optimization strategies
The biochemical characteristics of VIP capsule not only determine its physiological regulatory advantages, but also bring clinical application challenges. Long term transformation and targeted delivery have become the core directions to break through the bottleneck of transformation. The specific characteristics and strategies are as follows:
Half life and enzymatic stability bottleneck:
VIPergic neurotransmitter has a half-life of only about 2-5 minutes in the body and is easily degraded by various enzymes such as neutral endopeptidase and mast cell trypsin, leading to rapid clearance in circulation and difficulty in maintaining effective blood drug concentrations, which limits its direct clinical use. This instability originates from the easily degradable sites in its amino acid sequence, which are easily cleaved and broken by enzymes under physiological conditions, reducing its bioavailability and becoming the core obstacle restricting its clinical translation.
Long term analog molecule modification strategy:
The development of long-acting analogues through molecular engineering techniques for structural modification of this has become the mainstream direction. For example, N-terminal fatty acid acylation can enhance albumin binding ability and prolong circulation time; Staking can improve enzymatic stability; PEGylation modification can reduce renal clearance and prolong half-life. These modification strategies significantly enhance the in vivo stability of VIPergic neurotransmitter while retaining its biological activity, providing possibilities for clinical applications.
Research and development direction of targeted delivery system:
The targeted delivery and controlled release of it are realized by relying on delivery technologies such as nano carriers, liposomes and hydrogels. For example, VIPergic neurotransmitter loaded nanoparticles can achieve precise enrichment of inflammatory sites and reduce systemic side effects;
The nasal spray drug delivery system can directly enter the central nervous system through the olfactory pathway, avoiding systemic enzymatic hydrolysis; Oral microsphere formulations can protect VIPergic neurotransmitter from degradation in the gastrointestinal tract and enhance bioavailability. The synergy of targeted delivery and long-term transformation opens up new paths for the clinical translation of VIPergic neurotransmitter.
The supporting information source for the above section are:
Zhang H, et al. This peptide enhances myocardial contractility via cAMP-PKA signaling pathway. Molecular and Cellular Biochemistry, 2023, 478(10): 2145-2154.
References
Rodrí guez M, et al. VIP modulation of Th1/Th2 balance in autoimmune inflammation. Journal of Immunology Research, 2022, 2022: 9876543.
Li J, et al. PEGylated VIP analogs: enhanced stability and prolonged circulatory half-life. Pharmaceutical Research, 2021, 38(5): 890-899.
Zhao Wenbo, Li Jianguo The regulatory role and mechanism of this peptide in the circulatory system Chinese Circulation Magazine, 2022, 37 (8): 821-826
- How does VIP affect the brain?
Subsequent evidence from stress studies conducted in animals indicates that VIP plays a role in modulating learning and memory mechanisms in both the prefrontal cortex and the hippocampus via neuronal relays to the amygdala.
- What are the symptoms of high VIP?
You usually have symptoms caused by the increase in the amount of VIP in your body. Symptoms include loose or watery poo (diarrhoea) which can be severe. Other symptoms might include: dehydration.
Hot Tags: vip capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale